Geranylgeranyltransferase type 1
Geranylgeranyltransferase type 1 (GGTase-I) is an enzyme that plays a crucial role in the post-translational modification of proteins through a process known as prenylation. This modification involves the attachment of geranylgeranyl groups to the cysteine residues of specific protein substrates, a critical step for their proper localization and function within the cell. GGTase-I is particularly important in the modification of small GTPases, which are involved in various cellular processes including signal transduction, cell growth, and differentiation.
Function[edit | edit source]
GGTase-I specifically catalyzes the transfer of a 20-carbon geranylgeranyl moiety from geranylgeranyl pyrophosphate (GGPP) to the cysteine residues at the C-terminus of target proteins in a reaction that requires the presence of a CAAX motif (where C is cysteine, A is an aliphatic amino acid, and X is any amino acid). This modification increases the hydrophobicity of the target protein, facilitating its association with cell membranes and thus influencing its activity and interactions within the cell.
Structure[edit | edit source]
The enzyme is a heterodimer composed of an alpha (α) subunit and a beta (β) subunit. The α subunit is shared with another enzyme, farnesyltransferase, while the β subunit is unique to GGTase-I. This composition is critical for the enzyme's specificity towards its substrates.
Clinical Significance[edit | edit source]
Alterations in the activity of GGTase-I have been implicated in various diseases, including cancer. The enzyme's role in modifying proteins that regulate cell growth and survival makes it a potential target for therapeutic intervention. Inhibitors of GGTase-I are being explored as anticancer agents, with the rationale that blocking the prenylation of oncogenic proteins might suppress tumor growth and progression.
Research[edit | edit source]
Research into GGTase-I has focused on understanding its substrate specificity, mechanism of action, and role in disease. Studies have also been directed towards developing specific inhibitors that can selectively target GGTase-I without affecting other enzymes involved in prenylation, aiming to minimize potential side effects.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD